ASX:TLXBiotechs
Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After New AI Collaboration In Prostate Cancer Imaging
Telix Pharmaceuticals (ASX:TLX) has drawn fresh attention after announcing a collaboration with University Hospital Essen to apply artificial intelligence to the large PROMISE-PET registry for PSMA-PET imaging in prostate cancer.
See our latest analysis for Telix Pharmaceuticals.
The new AI collaboration comes after a period of mixed performance, with Telix’s 1-day share price return of 6.54% and 7-day return of 7.50% contrasting with a 90-day share price decline of 27.41% and a 1-year total...